China-based vaccines developer Jiangsu Recbio Technology has raised HK$765 million ($97.7 million) in an initial public offering (IPO) in Hong Kong on Thursday. The funds will go towards challenging the dominant foreign player Merck & Co in China’s highly-concentrated HPV (Human papillomavirus) vaccine market.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
